← Browse by Condition
Medical Condition

pulmonary arterial hypertension

Total Trials
8
Recruiting Now
8
Trial Phases
Phase 1, Phase 4, Phase 2

Hypertension remains the most common treatable cardiovascular risk factor globally, yet blood pressure control rates remain suboptimal despite multiple effective drug classes. Clinical trials now investigate novel mechanisms including aldosterone synthase inhibitors, renal denervation devices, and RNA-based therapies targeting angiotensinogen to achieve durable pressure reduction with minimal pill burden.

Active research includes zilebesiran (RNA interference targeting angiotensinogen), baxdrostat (aldosterone synthase inhibitor), ultrasound renal denervation (Symplicity HTN-4), and resistant hypertension approaches combining SGLT2 inhibitors with MRA spironolactone. Ambulatory blood pressure monitoring is increasingly used as the primary endpoint instead of clinic readings.

Frequently Asked Questions — pulmonary arterial hypertension Clinical Trials

How many clinical trials are currently recruiting for pulmonary arterial hypertension?
ClinicalMetric currently tracks 8 actively recruiting clinical trials for pulmonary arterial hypertension, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pulmonary arterial hypertension?
pulmonary arterial hypertension research spans Phase 1 (1 trial), Phase 2 (1 trial), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pulmonary arterial hypertension clinical trial?
Eligibility criteria for pulmonary arterial hypertension trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Phase 4
1
Top Sponsors
University of Minnesota 1 trial
University of Sao Paulo General Hospital 1 trial
AOP Orphan Pharmaceuticals AG 1 trial
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 1 trial
New York Medical College 1 trial

Recruiting Clinical Trials

NCT06481852 Phase 1
Recruiting
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
Enrollment
24 pts
Location
United States
Sponsor
University of Minnesota
View Trial →
NCT06850792
Recruiting
imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce
Enrollment
61 pts
Location
Brazil
Sponsor
University of Sao Paulo Genera...
View Trial →
NCT06317805 Phase 4
Recruiting
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
Enrollment
110 pts
Location
Austria, Czechia, Fr...
Sponsor
AOP Orphan Pharmaceuticals AG
View Trial →
NCT05665556
Recruiting
REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE)
Enrollment
170 pts
Location
Mexico
Sponsor
Instituto Nacional de Ciencias...
View Trial →
NCT02249923
Recruiting
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
Enrollment
2,500 pts
Location
United States, Canad...
Sponsor
New York Medical College
View Trial →
NCT07366879
Recruiting
Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial Hypertension
Enrollment
40 pts
Location
United Kingdom
Sponsor
Golden Jubilee National Hospit...
View Trial →
NCT06053580 Phase 2
Recruiting
Repurposing Valsartan May Protect Against Pulmonary Hypertension
Enrollment
60 pts
Location
United States
Sponsor
University of Washington
View Trial →
NCT05368467
Recruiting
National Registry and Cohort Study of Pulmonary Vascular Disease
Enrollment
1,000 pts
Location
China
Sponsor
Nanjing First Hospital, Nanjin...
View Trial →

Related Conditions

pulmonary arterial hypertension pah who group 1 ph (1) pulmonary arterial hypertension pah (1) connective tissue diseases (1) pulmonary vascular disease (1) right heart failure (1) right ventricular dysfunction (1) pulmonary vascular disorder (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology